Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer.
Miller ED, Fisher JL, Haglund KE, Grecula JC, Xu-Welliver M, Bertino EM, He K, Shields PG, Carbone DP, Williams TM, Otterson GA, Bazan JG. Miller ED, et al. Among authors: carbone dp. J Thorac Oncol. 2018 Mar;13(3):426-435. doi: 10.1016/j.jtho.2017.11.135. Epub 2018 Jan 8. J Thorac Oncol. 2018. PMID: 29326090 Free PMC article.
Nuclear survivin as a biomarker for non-small-cell lung cancer.
Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP, Hallahan DE. Lu B, et al. Among authors: carbone dp. Br J Cancer. 2004 Aug 2;91(3):537-40. doi: 10.1038/sj.bjc.6602027. Br J Cancer. 2004. PMID: 15266313 Free PMC article.
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F, Choy H. Mutter R, et al. Among authors: carbone dp. Clin Cancer Res. 2009 Mar 15;15(6):2158-65. doi: 10.1158/1078-0432.CCR-08-0629. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276291 Clinical Trial.
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.
Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, Sandler A, Billheimer D, Shyr Y, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TP. Salmon S, et al. J Thorac Oncol. 2009 Jun;4(6):689-96. doi: 10.1097/JTO.0b013e3181a526b3. J Thorac Oncol. 2009. PMID: 19404214 Free PMC article. Clinical Trial.
378 results